KEYLYNK-009: Pembrolizumab plus Olaparib in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer after Clinical Benefit from First-Line Pembrolizumab plus Chemotherapy
Although the primary endpoint was not met, postinduction pembrolizumab plus olaparib therapy resulted in similar PFS and OS compared with pembrolizumab plus chemotherapy in this setting. The positive trend for PFS and OS in participants with tBRCAm suggests a potential nonchemotherapy strategy for maintaining clinical benefit attained with first-line pembrolizumab plus chemotherapy induction treatment. No new safety signals were identified.
Authors
- Nadia Harbeck (ORCID: https://orcid.org/0000-0002-9744-7372)
- Antonio Llombart‐Cussac (ORCID: https://orcid.org/0000-0003-4515-8293)
- Aditya Bardia (ORCID: https://orcid.org/0000-0003-4885-1157)
- Shigehira Saji (ORCID: https://orcid.org/0000-0002-6732-8030)
- Eduardo Yañez Ruiz (ORCID: https://orcid.org/0009-0007-0045-233X)
- Oleksandr Dudnichenko (ORCID: https://orcid.org/0000-0001-8626-8435)
- Felipe Reyes-Cosmelli (ORCID: https://orcid.org/0000-0002-5104-3081)
- Mark E. Robson (ORCID: https://orcid.org/0000-0002-3109-1692)
- Florence Dalenc (ORCID: https://orcid.org/0000-0002-9854-4182)
- David W. Cescon (ORCID: https://orcid.org/0000-0002-1080-0998)
- Seock‐Ah Im (ORCID: https://orcid.org/0000-0002-5396-6533)
- Yasuo Miyoshi (ORCID: https://orcid.org/0000-0001-8535-4008)
- Amin Haiderali (ORCID: https://orcid.org/0000-0002-6858-1564)
- Néstor Eduardo Llinás Quintero (ORCID: https://orcid.org/0000-0001-5408-0606)
- Vassiliki Karantza (ORCID: https://orcid.org/0000-0003-4017-7858)
- Jaime Mejia (ORCID: https://orcid.org/0000-0002-1315-6878)
- Janice M. Walshe (ORCID: https://orcid.org/0009-0002-1938-8730)
- Young‐Hyuck Im (ORCID: https://orcid.org/0000-0001-6459-8118)
- Hope S. Rugo (ORCID: https://orcid.org/0000-0001-6710-4814)
- Sergii Kulyk (ORCID: https://orcid.org/0009-0000-4737-733X)
- Fan Li (ORCID: https://orcid.org/0000-0001-5430-8826)
Institutions
- Universidad de La Frontera (CL)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- City Of Hope National Medical Center (US)
- Fukushima Medical University (JP)
- Memorial Sloan Kettering Cancer Center (US)
- Hyogo Medical University (JP)
- University of California, Los Angeles (US)
- Samsung Medical Center (KR)
- Princess Margaret Cancer Centre (CA)
- Seoul National University Hospital (KR)
- LMU Klinikum (DE)
- Instituto de Cancerología Las Américas (CO)
- Fundación Con Vida (CO)
- Chuiko Institute of Surface Chemistry (UA)
- G.V. Kurdyumov Institute for Metal Physics (UA)
- City of Hope (US)
- St. Vincent's University Hospital (IE)
- USC Norris Comprehensive Cancer Center (US)
- Hospital Arnau de Vilanova (ES)
- Merck Institute for Science Education (US)
- Institute of Neurology, Psychiatry and Narcology (UA)
- Institut Claudius Regaud (FR)
- Fundación Arturo López Pérez (CL)
- Otemae University (JP)
- Vernadsky National Library of Ukraine (UA)
- Ludwig-Maximilians-Universität München (DE)
- Hyogo University (JP)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-12-17
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-1818
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00